220 related articles for article (PubMed ID: 11059259)
1. [Effect of therapeutic drug monitoring of amitriptyline and genotyping on efficacy and safety of depression therapy].
Ostapowicz A; Zejmo M; Wrześniewska J; Białecka M; Górnik W; Gawrońska-Szklarz B
Psychiatr Pol; 2000; 34(4):595-605. PubMed ID: 11059259
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?
Müller MJ; Dragicevic A; Fric M; Gaertner I; Grasmäder K; Härtter S; Hermann E; Kuss HJ; Laux G; Oehl W; Rao ML; Rollmann N; Weigmann H; Weber-Labonte M; Hiemke C
Pharmacopsychiatry; 2003 May; 36(3):98-104. PubMed ID: 12806567
[TBL] [Abstract][Full Text] [Related]
3. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse.
Rao ML; Deister A; Laux G; Staberock U; Höflich G; Möller HJ
Pharmacopsychiatry; 1996 May; 29(3):97-102. PubMed ID: 8738313
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic monitoring of tricyclic antidepressant drugs].
Grzesiak M; Beszłej JA; Szewczuk-Bogusławska M
Psychiatr Pol; 2003; 37(5):825-37. PubMed ID: 14631602
[TBL] [Abstract][Full Text] [Related]
5. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
[TBL] [Abstract][Full Text] [Related]
6. [Grapefruit juice as a contraindication? An approach in psychiatry].
Vandel P; Regina W; Reix I; Vandel S; Sechter D; Bizouard P
Encephale; 1999; 25(1):67-71. PubMed ID: 10205736
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic-resistant depression: treatment resistance or inadequate treatment?
Lydiard RB
J Clin Psychiatry; 1985 Oct; 46(10):412-7. PubMed ID: 3900051
[TBL] [Abstract][Full Text] [Related]
8. [Clinical pharmacokinetics of tricyclic antidepressants Part II. Drug therapy monitoring].
Szymura-Oleksiak J; Wasieczko A; Wyska E; Zieba A
Psychiatr Pol; 1994; 28(1):17-26. PubMed ID: 8190816
[TBL] [Abstract][Full Text] [Related]
9. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
10. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.
Künzel HE; Ackl N; Hatzinger M; Held K; Holsboer-Trachsler E; Ising M; Kaschka W; Kasper S; Konstantinidis A; Sonntag A; Uhr M; Yassouridis A; Holsboer F; Steiger A
J Psychiatr Res; 2009 Apr; 43(7):702-10. PubMed ID: 19038406
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring in depression.
Radziwoń-Zaleska M; Matsumoto H; Skalski M; Androsiuk W; Dziklińska A; Kunicki PK
Pol J Pharmacol; 2000; 52(4):255-66. PubMed ID: 11345481
[TBL] [Abstract][Full Text] [Related]
12. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.
Chen S; Chou WH; Blouin RA; Mao Z; Humphries LL; Meek QC; Neill JR; Martin WL; Hays LR; Wedlund PJ
Clin Pharmacol Ther; 1996 Nov; 60(5):522-34. PubMed ID: 8941025
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
Vandel P
World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: a therapeutic window relationship.
Ulrich S; Northoff G; Wurthmann C; Partscht G; Pester U; Herscu H; Meyer FP
Pharmacopsychiatry; 2001 Jan; 34(1):33-40. PubMed ID: 11229620
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
[TBL] [Abstract][Full Text] [Related]
16. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.
Preskorn SH; Fast GA
J Clin Psychiatry; 1991 Jun; 52 Suppl():23-33. PubMed ID: 1904862
[TBL] [Abstract][Full Text] [Related]
18. Tricyclic antidepressant-induced seizures and plasma drug concentration.
Preskorn SH; Fast GA
J Clin Psychiatry; 1992 May; 53(5):160-2. PubMed ID: 1592842
[TBL] [Abstract][Full Text] [Related]
19. [Results of using tricyclic antidepressive drugs in the treatment of endogenous depression (comparative analysis of 7 drugs)].
Beresewicz M; Bidzińska E; Koszewska I; Puzyński S
Psychiatr Pol; 1991; 25(3-4):13-8. PubMed ID: 1687987
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentrations of tricyclic antidepressants in clinical practice.
Hollister LE
J Clin Psychiatry; 1982 Feb; 43(2):66-9. PubMed ID: 7056706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
